McKinsey January 9, 2025
Pharma R&D leaders and their suppliers see transparency as a key to unlocking more effective collaborations and cost efficiencies.
Innovation is flourishing in the biopharmaceutical industry. Over the past decade, the volume of Phase I candidates in the drug development pipeline has grown by 60 percent, promising potential breakthroughs in treating a wide range of diseases. At the same time, there has been a noticeable shift across the industry toward outsourcing R&D activities. Driven by the need for flexibility, specialized expertise, and wider global reach, pharmaceutical organizations have engaged contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), and other suppliers to cover nearly every aspect of drug development, from target identification to clinical-trial execution. Outsourcing also allows R&D...
Today's Sponsors
Today's Sponsor